• Nxera Pharma swung to a net profit of JPY 2.33 billion for the nine months ended September 30, 2026.
• Revenue rose 27% year-over-year to JPY 27.74 billion, while milestone revenue more than doubled to JPY 9.5 billion.
• In October, it licensed Fabry disease candidate lucerastat from Idorsia, with regulatory filings targeted as early as 2029.
• The full-year 2026 revenue forecast remains unchanged at JPY 33.8 billion to JPY 48.8 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.